当前位置： SCI文献检索 > Therapeutic Innovation & Regulatory Science期刊下所有文献 > Regulatory Issues of Voluntary Certification of Food Supplements in Russia.

Regulatory Issues of Voluntary Certification of Food Supplements in Russia.

Abstract：

:When registering food supplements in Russia, restrictions on the labeling and consumer leaflet contents are tightly controlled by the regulatory agencies. Thus, misleading advertising is the most difficult problem with the turnover of these products if information in the commercials does not correspond to the information on indications for use that were agreed upon during state registration (or sanitary and epidemiologic control). An established procedure of voluntary certification enables additional health claims, thus expanding the information in the label and user leaflet. Voluntary certification is the evidence base for the specific characteristics of the products with regard to their efficacy represented by an independent party. This process allows the manufacturer to inform the consumer about the beneficial properties and efficacy of food supplements and enables the buyer to make an informed choice and to avoid buying counterfeit products by purchasing high-quality safe products with proven efficacy; therefore, the buyer can receive a product that is the best match for his needs and expectations. However, since the mid-2000s, several voluntary certification systems have been developed, approved, and included in the Unified Register of Voluntary Certification Systems maintained by the Federal Agency for Technical Regulation and Metrology, Rosstandart. Thus, manufacturers can choose an authority. In addition to the conventional approach to certification requirements and schemes, various outcomes of approved claims and subsequent certification maintenance are possible. The present article analyzes universal principles of voluntary certification, its legal basis, and authority-specific outcomes of the process.

journal_name

Ther Innov Regul Sci

journal_title

Therapeutic innovation & regulatory science

authors

Lozda R

doi

10.1007/s43441-019-00043-z

subject

Has Abstract

pub_date

2020-01-01 00:00:00

pages

177-183

issue

1

eissn

2168-4790

issn

2168-4804

pii

10.1007/s43441-019-00043-z

journal_volume

54

pub_type

杂志文章,评审

相关文献

Therapeutic Innovation & Regulatory Science文献大全
  • phactMI Benchmarking Survey on Content Development and Inquiry Management.

    abstract：BACKGROUND:Medical information (MI) departments across pharmaceutical companies respond to medical inquiries about a company's products to healthcare providers, payors, patients, and caregivers. Responses provided are constructed to be relevant, accurate, scientifically balanced and delivered in a timely manner. Benchm...

    journal_title：Therapeutic innovation & regulatory science

    pub_type： 杂志文章

    doi：10.1007/s43441-020-00137-z

    authors： Byun J,Jong JA,Gangat A,Flowers T,Gazo A,Shah I

    更新日期：2020-11-01 00:00:00

  • Rheumatoid Arthritis Disease Progression Modeling.

    abstract：:Time progression models provide a significant advantage in developing clinical trials and can also be used to elicit comparisons among therapeutic agents. The authors performed a meta-analysis to construct a time progression model for rheumatoid arthritis (RA), an area of significant interest for pharmaceutical develo...

    journal_title：Therapeutic innovation & regulatory science

    pub_type： 杂志文章

    doi：10.1177/2168479013499571

    authors： Reeve R,Pang L,Ferguson B,O'Kelly M,Berry S,Xiao W

    更新日期：2013-11-01 00:00:00

  • The Roles of Regulatory Science Research in Drug Development at the Pharmaceuticals and Medical Devices Agency of Japan.

    abstract：:Recently, it is becoming increasingly difficult to develop innovative drugs. Thus, the role of regulatory science research in drug development and postmarketing settings has become more important. In this article, the authors discuss the roles of regulatory science research at the Pharmaceuticals and Medical Devices A...

    journal_title：Therapeutic innovation & regulatory science

    pub_type： 杂志文章

    doi：10.1177/2168479012469950

    authors： Asahina Y,Tanaka A,Uyama Y,Kuramochi K,Maruyama H

    更新日期：2013-01-01 00:00:00

  • New Drug and Biologics Approvals in 2019: A Systematic Analysis of Patient Experience Data in FDA Drug Approval Packages and Product Labels.

    abstract：BACKGROUND:The FDA Patient-Focused Drug Development Initiative was launched to ensure the incorporation of the patient voice into drug development and evaluation. Since 2017, the FDA must publish a statement outlining patient experience data (PED) considered in the approval of new drugs. This study investigated the pre...

    journal_title：Therapeutic innovation & regulatory science

    pub_type： 杂志文章

    doi：10.1007/s43441-020-00244-x

    authors： Schultz-Knudsen K,Sabaliauskaite U,Hellsten J,Lassen AB,Morant AV

    更新日期：2020-11-23 00:00:00

  • Insights and Best Practices for Planning and Implementing Patient Advisory Boards.

    abstract：:A growing number of organizations-including pharmaceutical and biotechnology companies, foundations and associations-are routinely implementing patient advisory boards (PAB) given their high reported value for minimal relative investment. Organizations are typically implementing PABs to solicit patient voices and pers...

    journal_title：Therapeutic innovation & regulatory science

    pub_type： 杂志文章

    doi：10.1177/2168479017720475

    authors： Anderson A,Getz KA

    更新日期：2018-07-01 00:00:00

  • ADHD & Pharmacotherapy: Past, Present and Future: A Review of the Changing Landscape of Drug Therapy for Attention Deficit Hyperactivity Disorder.

    abstract：:Attention deficit hyperactivity disorder (ADHD) is the most common neurobiological disorder in children, with a prevalence of ~6-7%1,2 that has remained stable for decades2. The social and economic burden associated with patients3, families, and broader systems (healthcare/educational) is substantial, with the annual ...

    journal_title：Therapeutic innovation & regulatory science

    pub_type： 杂志文章

    doi：10.1177/2168479015599811

    authors： Connolly JJ,Glessner JT,Elia J,Hakonarson H

    更新日期：2015-09-01 00:00:00

  • Community Opinions on the Collection and Use of Historical Control Data in Nonclinical Toxicity Studies.

    abstract：BACKGROUND:Access and use of historical control data was identified as a top stakeholder concern across organizations according to results of a survey of needs and challenges related to nonclinical data conducted by the FDA/PhUSE Nonclinical Working Group in 2011. There is a perception there may be additional ways to c...

    journal_title：Therapeutic innovation & regulatory science

    pub_type： 杂志文章

    doi：10.1177/2168479015600203

    authors： Mihalcik LM,Bausman M,Brown P,Everds N,Feldmann J,Henck J,Potenta D,Sims J,Zandee J

    更新日期：2016-03-01 00:00:00

  • Over-the-Counter Drugs: Regulatory Analysis of Warning Letters Between Fiscal Years 2015-2019.

    abstract：BACKGROUND:According to 21 Code of Federal Regulation (CFR) Part 211, Over-the-Counter (OTC) drug manufacturers must establish and follow current good manufacturing practices (cGMP) to produce quality products while meeting regulatory standards. The warning letters issued by the U.S. Food and Drug Administration (FDA) ...

    journal_title：Therapeutic innovation & regulatory science

    pub_type： 杂志文章

    doi：10.1007/s43441-020-00231-2

    authors： Bai HK,Ahearn JD,Bartlett MG

    更新日期：2020-10-23 00:00:00

  • Methods for Employing Information About Uncertainty of Ascertainment of Events in Clinical Trials.

    abstract：BACKGROUND:Uncertain ascertainment of events in clinical trials has been noted for decades. To correct possible bias, Clinical Endpoint Committees (CECs) have been employed as a critical element of trials to ensure consistent and high-quality endpoint evaluation, especially for cardiovascular endpoints. However, the ef...

    journal_title：Therapeutic innovation & regulatory science

    pub_type： 杂志文章

    doi：10.1007/s43441-020-00206-3

    authors： Chen Y,Lawrence J,Hung HMJ,Stockbridge N

    更新日期：2021-01-01 00:00:00

  • Adaptive Design: Results of 2012 Survey on Perception and Use.

    abstract：:Adaptive designs are increasingly used in clinical trials. The Drug Information Association's Adaptive Design Scientific Working Group (ADSWG) works to foster collaboration among regulatory agencies, academia, and pharmaceutical and biotech companies to further the science of adaptive clinical development. The ADSWG S...

    journal_title：Therapeutic innovation & regulatory science

    pub_type： 杂志文章

    doi：10.1177/2168479014522468

    authors： Morgan CC,Huyck S,Jenkins M,Chen L,Bedding A,Coffey CS,Gaydos B,Wathen JK

    更新日期：2014-07-01 00:00:00

  • Improving Drug Development and Patient Access With the Right People, Processes, and Culture: What Needs to Happen Right Now to Bring Better Medicines to the Patients Who Need Them.

    abstract：:In a global environment where health care costs are soaring, R&D efforts are flatlining. Meanwhile, payers are demanding more value for their money. In this environment, the traditional siloed drug development model is not sustainable. Yet innovations such as adaptive trial designs, real-world data collection, precisi...

    journal_title：Therapeutic innovation & regulatory science

    pub_type： 杂志文章

    doi：10.1177/2168479018814224

    authors： Grignolo A,Siu A

    更新日期：2019-05-01 00:00:00

  • Regulatory Trends in Drug Development in Asia Pacific.

    abstract：:The Asia Pacific (AP) region is diverse and dynamic. It comprises over 40 economies, with about 24 markets that are relatively more active in terms of promulgating and implementing regulations that impact the biopharmaceutical industry and advance drug development. Although many country- and territory-specific regulat...

    journal_title：Therapeutic innovation & regulatory science

    pub_type： 杂志文章

    doi：10.1177/2168479018791539

    authors： Han FV,Weiss K

    更新日期：2019-07-01 00:00:00

  • Evaluation and Characterization of Health Economics and Outcomes Research in SAARC Nations.

    abstract：OBJECTIVE:To identify, evaluate, and characterize the variety, quality, and intent of the health economics and outcomes research studies being conducted in SAARC (South Asian Association for Regional Cooperation) nations. METHODS:Studies published in English language between 1990 and 2015 were retrieved from Medline d...

    journal_title：Therapeutic innovation & regulatory science

    pub_type： 杂志文章,评审

    doi：10.1177/2168479017731583

    authors： Mehta M,Nerurkar R

    更新日期：2018-05-01 00:00:00

  • Evaluation of the Performance of the South Africa Regulatory Agency: Recommendations for Improved Patients' Access to Medicines.

    abstract：BACKGROUND:Timely access to new medicines may be addressed through strengthening of registration efficiencies and timelines by establishing and refining value-added registration processes, resources, and systems. The aims of this study were to evaluate the timelines of the milestones of the South African review process...

    journal_title：Therapeutic innovation & regulatory science

    pub_type： 杂志文章

    doi：10.1007/s43441-019-00013-5

    authors： Keyter A,Salek S,Gouws J,Banoo S,Walker S

    更新日期：2020-07-01 00:00:00

  • Implementing the Principle of the 3 Rs Through the Indian Pharmacopoeia.

    abstract：:Quality and safety tests are required for regulatory approval of drugs and pharmaceuticals in the country to guarantee minimum safety standards, and most of these tests include animal usage. In the case of biological medicines, these safety and quality tests have to be performed on a batch-to-batch basis and require a...

    journal_title：Therapeutic innovation & regulatory science

    pub_type： 杂志文章

    doi：10.1177/2168479015572371

    authors： Rastogi S,Kalaivani M,Bhatia AK,Prakash J,Singh GN

    更新日期：2015-09-01 00:00:00

  • Study Designs in Multi-arm Trials for Breast Cancer: A Systematic Literature Review of Major Journals.

    abstract：BACKGROUND:Several articles showed that statistical efficiency of multi-arm randomized clinical trials (RCTs) is much better than conventional two-arm RCTs. Multi-arm RCTs attract interest mainly when the experimental treatment regimen is not optimized or several pipelines under development exist. Breast cancer is a po...

    journal_title：Therapeutic innovation & regulatory science

    pub_type： 杂志文章

    doi：10.1007/s43441-020-00141-3

    authors： Nomura S,Miyauchi Y,Ajisawa Y,Isogaya K,Sozu T

    更新日期：2020-09-01 00:00:00

  • Implementation of the European QRD Template in Package Leaflets of Centralized Approved Medicines.

    abstract：BACKGROUND:Package leaflets of medicines distributed within the European Union should use the template headings and standard texts created by the Working Group on the Quality Review of Documents (QRD). The following study investigated how the QRD template is implemented in this patient information. METHODS:All English...

    journal_title：Therapeutic innovation & regulatory science

    pub_type： 杂志文章

    doi：10.1177/2168479015620247

    authors： Wolf A,Fuchs J,Schweim HG

    更新日期：2016-01-01 00:00:00

  • Expanded Access Programs: Ethical and Practical Considerations for Biopharmaceutical Sponsors.

    abstract：:Expanded access is a regulatory mechanism by which an investigational drug can be made available outside of a clinical trial to treat patients with serious or life-threatening conditions for which there are no satisfactory treatment options. An expanded access program (EAP) is the formal plan under which preapproval a...

    journal_title：Therapeutic innovation & regulatory science

    pub_type： 杂志文章

    doi：10.1177/2168479015578154

    authors： Klopfenstein M,Van Campen LE,Garnett T

    更新日期：2015-05-01 00:00:00

  • Considerations and Regulatory Challenges for Innovative Medicines in Expedited Approval Programs: Breakthrough Therapy and Sakigake Designation.

    abstract：BACKGROUND:In the breakthrough therapy designation (BTD) and Sakigake designation programs, rolling submission and close communication between applicants and regulatory authorities enable the timely access of patients to innovative medicines. However, challenges in the quality development, including chemistry, manufact...

    journal_title：Therapeutic innovation & regulatory science

    pub_type： 杂志文章

    doi：10.1007/s43441-019-00019-z

    authors： Kajiwara E,Shikano M

    更新日期：2020-07-01 00:00:00

  • Principled Structured Incorporation of Clinical Knowledge Into Strategic Development Decisions.

    abstract：:Efficient use of limited pharmaceutical product development resources requires integrating multiple attributes, such as efficacy, safety, pharmacology, and so on, to decide at any stage whether the development of a product should proceed aggressively or slowly or be terminated. The decision process proceeds most effec...

    journal_title：Therapeutic innovation & regulatory science

    pub_type： 杂志文章

    doi：10.1177/2168479014558273

    authors： Gould AL,Krishna R,Khan A,Saltzman J

    更新日期：2015-03-01 00:00:00

  • Building a Better Approach for the Benefit of Patients: 10 Pillars to Strengthen Regulatory Review Systems Globally.

    abstract：:In the current pharmaceutical regulatory environment, patients continue to benefit from great advances in medical care. Sophisticated regulatory review systems have also evolved to ensure that safe and effective medicines are approved. However, these systems are not optimized in all countries. Gaps in individual regul...

    journal_title：Therapeutic innovation & regulatory science

    pub_type： 杂志文章

    doi：10.1007/s43441-019-00055-9

    authors： O'Brien J,Lumsden RS,Diehl DH,Macdonald JC

    更新日期：2020-03-01 00:00:00

  • Expediting Drug Development: FDA's New Regenerative Medicine Advanced Therapy Designation.

    abstract：:In March 2017, the US FDA introduced the new Regenerative Medicine Advanced Therapy (RMAT) designation thus recognizing the enormous potential of these medicines and the need for efficient regulatory tools to accelerate their development and their commercial availability. The development of regenerative medicines is v...

    journal_title：Therapeutic innovation & regulatory science

    pub_type： 杂志文章

    doi：10.1177/2168479018779373

    authors： Vaggelas A,Seimetz D

    更新日期：2019-05-01 00:00:00

  • Interdisciplinary Safety Evaluation and Quantitative Safety Monitoring: Introduction to a Series of Papers.

    abstract：:The American Statistical Association and DIA have created an interdisciplinary working group of drug safety experts from academia, industry and regulatory backgrounds to explore the future direction for safety monitoring. This introduction to the series explains the background and rationale for this special section. ...

    journal_title：Therapeutic innovation & regulatory science

    pub_type： 杂志文章

    doi：10.1177/2168479018793130

    authors： Seltzer JH,Li J,Wang W

    更新日期：2019-03-29 00:00:00

  • Smart Program Design Through a Common Information Model.

    abstract：:Although much information is already available publically from information-sharing initiatives such as ClinicalTrials.gov, information about clinical programs is unstructured, inconsistent, and incomplete. Clinical research within bioscience companies, health care, academia, and governmental agencies could benefit fro...

    journal_title：Therapeutic innovation & regulatory science

    pub_type： 杂志文章

    doi：10.1177/2168479014539158

    authors： Vasko L,Sundgren M,Bachmann P,Balinski K,Bleich N,Blom T,Eriksson H,Ferendo R,Forsberg K,King D,Mordiva A,Proeve J,Thomas L,Witch E,Simán M

    更新日期：2015-01-01 00:00:00

  • Regulatory Definitions and Good Pharmacovigilance Practices in Social Media: Challenges and Recommendations.

    abstract：:Social media presents new challenges to the biopharmaceutical industry for conducting pharmacovigilance activities. The authors reviewed worldwide regulatory guidance documents related to monitoring of adverse events posted on social media sites and identified gaps in current regulatory definitions for pharmacovigilan...

    journal_title：Therapeutic innovation & regulatory science

    pub_type： 杂志文章

    doi：10.1177/2168479015587362

    authors： Naik P,Umrath T,van Stekelenborg J,Ruben R,Abdul-Karim N,Boland R,Ibara M,Ekuta J,Washburn D,Stergiopoulos S

    更新日期：2015-11-01 00:00:00

  • Alternative New Mono-scaled Quantitative Benefit-Risk Assessment of Human Papillomavirus Vaccine in Japan.

    abstract：BACKGROUND:The human papillomavirus (HPV) vaccine coverage is very low in Japan since the government suspended the active encouragement of the vaccination. We aimed to conduct a benefit-risk assessment of HPV vaccination and explore different consequent scenarios to identify potential improvements to the current Japane...

    journal_title：Therapeutic innovation & regulatory science

    pub_type： 杂志文章

    doi：10.1007/s43441-020-00189-1

    authors： Matsumoto T,Matsumaru N,Scuffham P,Neels P,Tsukamoto K

    更新日期：2021-01-01 00:00:00

  • Baseline Assessment of the Evolving 2017 eClinical Landscape.

    abstract：:The volume and diversity of data collected to support each clinical study has increased dramatically in response to the rising scope and complexity of global drug development programs. The Tufts Center for the Study of Drug Development conducted an online survey of 257 unique global companies-77% drug development spon...

    journal_title：Therapeutic innovation & regulatory science

    pub_type： 杂志文章

    doi：10.1177/2168479018769292

    authors： Wilkinson M,Young R,Harper B,Machion B,Getz K

    更新日期：2019-01-01 00:00:00

  • Complex Generic Products: Insight of Current Regulatory Frameworks in US, EU and Canada and the Need of Harmonisation.

    abstract：:The regulatory agencies all over the world have defined the pathway and regulations for the approval of simple small-molecule generics. In addition, the agencies are striving to form perspicuous regulatory frameworks for the approval of biosimilars. In this view, there are no defined regulations for the approval of co...

    journal_title：Therapeutic innovation & regulatory science

    pub_type： 杂志文章,评审

    doi：10.1007/s43441-020-00114-6

    authors： Lunawat S,Bhat K

    更新日期：2020-09-01 00:00:00

  • Strategic Shift of Statistical Review on Data Quality Assessment for New Drug Applications in China.

    abstract：:Data quality is critical for clinical trials to obtain robust conclusions about drug safety and efficacy evaluation. Effective data quality evaluation has been one of the major obstacles to new drug approvals in China, which hinders innovation in drug discovery and development ultimately. To improve the data quality s...

    journal_title：Therapeutic innovation & regulatory science

    pub_type： 杂志文章

    doi：10.1177/2168479018778528

    authors： Wang J,Wang G,Li M,Han J,Zeng X,Pan J,Yang J

    更新日期：2019-03-01 00:00:00

  • An Overview and Analysis Regarding the Use of Adjudication Methods in EU and US Drug Approvals.

    abstract：BACKGROUND:Several regulatory guidelines recommend that assessments of endpoints supporting drug approval should be verifiable by applicants and the regulatory agencies to minimize the potential for bias. This becomes especially critical when assessments are not based on measurable data but are derived from the interpr...

    journal_title：Therapeutic innovation & regulatory science

    pub_type： 杂志文章

    doi：10.1177/2168479015580382

    authors： Krumholz-Bahner S,Garibbo M,Getz KA,Widler BE

    更新日期：2015-11-01 00:00:00